Status:

UNKNOWN

Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression

Lead Sponsor:

Bnai Zion Medical Center

Collaborating Sponsors:

Janssen-Cilag Ltd.

Conditions:

Ankylosing Spondylitis

Eligibility:

MALE

18+ years

Phase:

PHASE4

Brief Summary

It will be a pilot, 2 year, prospective, randomized, double-blind, placebo-controlled (for pamidronate) study. All patients with AS will receive treatment with TNF inhibitor, while randomization will ...

Detailed Description

It will be a pilot, 2 year, prospective, randomized, double-blind, placebo-controlled (for pamidronate) study. All patients with AS will receive treatment with tumor necrosis factor (TNF) inhibitor, a...

Eligibility Criteria

Inclusion

  • presence of spinal syndesmophytes
  • normal renal and liver function
  • eligibility to receive anti-TNF treatment according to local guidelines

Exclusion

  • unwilling to sigh the informed consent
  • presence of significant systemic or organ-limited disorders, other than AS
  • any contraindication for anti-TNF or pamidronate treatment
  • presence of acute dental/periodontal disease

Key Trial Info

Start Date :

December 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2017

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT02313727

Start Date

December 1 2014

End Date

September 1 2017

Last Update

December 10 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bnai Zion Medical Center

Haifa, Israel, 38041

Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression | DecenTrialz